PH12021552902A1 - Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor - Google Patents

Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Info

Publication number
PH12021552902A1
PH12021552902A1 PH1/2021/552902A PH12021552902A PH12021552902A1 PH 12021552902 A1 PH12021552902 A1 PH 12021552902A1 PH 12021552902 A PH12021552902 A PH 12021552902A PH 12021552902 A1 PH12021552902 A1 PH 12021552902A1
Authority
PH
Philippines
Prior art keywords
amino
methylpyrazin
decan
azaspiro
chloropyridin
Prior art date
Application number
PH1/2021/552902A
Other languages
English (en)
Inventor
Steven G Ballmer
Shaoling Li
Original Assignee
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolution Medicines Inc filed Critical Revolution Medicines Inc
Publication of PH12021552902A1 publication Critical patent/PH12021552902A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PH1/2021/552902A 2019-06-07 2020-06-04 Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor PH12021552902A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962858837P 2019-06-07 2019-06-07
PCT/US2020/036137 WO2020247643A1 (en) 2019-06-07 2020-06-04 Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Publications (1)

Publication Number Publication Date
PH12021552902A1 true PH12021552902A1 (en) 2022-04-04

Family

ID=71787182

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/552902A PH12021552902A1 (en) 2019-06-07 2020-06-04 Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Country Status (15)

Country Link
US (2) US11220501B2 (https=)
EP (1) EP3980128A1 (https=)
JP (2) JP2022534788A (https=)
KR (1) KR20220019017A (https=)
CN (2) CN115141205A (https=)
AU (1) AU2020288631A1 (https=)
BR (1) BR112021022635A2 (https=)
CA (1) CA3142430A1 (https=)
IL (1) IL288568A (https=)
MA (1) MA56113A (https=)
MX (1) MX2021014855A (https=)
PH (1) PH12021552902A1 (https=)
SG (1) SG11202112461QA (https=)
TW (1) TW202112785A (https=)
WO (1) WO2020247643A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
CN115141205A (zh) 2019-06-07 2022-10-04 锐新医药公司 Shp2抑制剂的固体形式
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
KR20240055778A (ko) 2021-09-01 2024-04-29 노파르티스 아게 Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
TW200716594A (en) * 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
NZ713361A (en) * 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
ES2699351T3 (es) * 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP4302834A3 (en) * 2016-07-12 2024-07-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
MX2020010719A (es) 2018-04-10 2020-11-06 Revolution Medicines Inc Composiciones de inhibidores de shp2, metodos para tratar el cancer y metodos para identificar a un sujeto con mutaciones en shp2.
CN115141205A (zh) 2019-06-07 2022-10-04 锐新医药公司 Shp2抑制剂的固体形式

Also Published As

Publication number Publication date
SG11202112461QA (en) 2021-12-30
US12528807B2 (en) 2026-01-20
WO2020247643A1 (en) 2020-12-10
CN114190090A (zh) 2022-03-15
JP2025138706A (ja) 2025-09-25
CA3142430A1 (en) 2020-12-10
US11220501B2 (en) 2022-01-11
AU2020288631A1 (en) 2021-12-09
BR112021022635A2 (pt) 2022-01-04
TW202112785A (zh) 2021-04-01
CN115141205A (zh) 2022-10-04
MA56113A (fr) 2022-04-13
IL288568A (en) 2022-02-01
EP3980128A1 (en) 2022-04-13
JP2022534788A (ja) 2022-08-03
KR20220019017A (ko) 2022-02-15
MX2021014855A (es) 2022-01-18
US20210253574A1 (en) 2021-08-19
US20220298159A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
PH12021552902A1 (en) Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
MX2022011534A (es) Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa.
PH12021550045A1 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2022008066A (es) Compuestos triciclicos sustituidos.
CR20230261A (es) Cocristal de un inhibidor de cdk
WO2019191229A8 (en) Compounds for treating huntington's disease
EP4541422A3 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
WO2020016749A3 (en) Chemical process for preparing phenylpiperidinyl indole derivatives
ZA202007566B (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
MY209603A (en) Hydroxypyridoxazepines as nrf2 activators
WO2018209363A3 (en) PROPIONIC ACID DERIVATIVES AND ASSOCIATED METHODS OF USE
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
PH12021552513A1 (en) Pyrrole compounds
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
MY198008A (en) Crystal of benzofuran derivative free base and preparation method
JP2019519512A5 (https=)
PH12022551241A1 (en) Egfr inhibitors
TN2018000188A1 (en) Isoindole compounds
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
ZA202105887B (en) Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
WO2020016847A3 (en) Purification process for preparation of eribulin and intermediates thereof
EP4353230A3 (en) Solid state forms of asciminib and process for preparation thereof
MX2025013649A (es) Compuesto de oxazolona sustituida para reducir los niveles de proteinas con dedos de zinc ikaros (ikzf) 1-4
WO2021055797A9 (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)